Group 1: Industry Overview - The healthcare sector has experienced a bifurcation, with innovative drugs reviving while consumer healthcare remains in a downturn [1][12] - The innovative drug sector has seen significant growth, with a total transaction volume of $60.8 billion in the first half of the year, a 129% increase year-on-year [2][4] - The number of innovative drug companies with a market capitalization exceeding 100 billion yuan has increased to nine [3] Group 2: Innovative Drug Companies Performance - Hengrui Medicine reported revenue of 15.76 billion yuan and a net profit of 4.45 billion yuan in the first half of the year, with a year-on-year growth of 15.88% and 29.67% respectively [5] - BeiGene achieved revenue of 17.52 billion yuan and a net profit of 450 million yuan, marking its first half-year profit since its listing [7] - China Biologic Products reported revenue of 17.57 billion yuan, a 10.7% increase year-on-year, with innovative product revenue reaching 7.8 billion yuan, up 27.2% [6] Group 3: Consumer Healthcare Challenges - The vaccine sector, particularly for Zhifei Biological, saw a 73.06% decline in revenue to 4.92 billion yuan, resulting in a net loss of 597 million yuan [12] - Other consumer healthcare companies like Opcon Vision and Anke Bio also reported revenue declines, indicating a broader trend of stagnation in the sector [13] - The decline in consumer healthcare is attributed to price wars and changing consumer perceptions regarding product efficacy [13] Group 4: CRO Industry Dynamics - The CRO sector has experienced a divergence, with leading companies like WuXi AppTec reporting significant growth while smaller firms struggle [9][11] - WuXi AppTec's revenue reached 20.8 billion yuan, with a net profit increase of 101.92% [9] - The demand for CRO services is driven by the need for customized technology platforms and compliance capabilities in high-value segments like ADC and GLP-1 [10][11]

Core Viewpoint - The Hong Kong stock market showed volatility on September 2, with the pharmaceutical sector leading gains, particularly the Hong Kong Stock Connect Medical ETF, which reached a new historical high [1] Group 1: Market Performance - The Hong Kong Stock Connect Medical ETF (159506) rose nearly 2%, achieving a new historical high [1] - Key constituent stocks such as BeiGene and 3SBio increased by over 4%, while WuXi AppTec and Kelun-Bio rose by over 2% [1] Group 2: Company Developments - Heng Rui Medicine announced that it received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554, which is the first EZH2 inhibitor developed in China [2][3] - The drug targets peripheral T-cell lymphoma (PTCL), which accounts for approximately 25%-30% of non-Hodgkin lymphoma patients in China, with a median onset age of 52 years [3] - Heng Rui's total R&D investment for SHR2554 has reached approximately 21.3 million yuan [3] Group 3: Future Outlook - The first half of 2025 is expected to see explosive growth in the export of Chinese innovative drugs, with significant increases in licensing-out transaction amounts [4] - The Chinese pharmaceutical industry is becoming a major source of global innovative drugs, contributing 50% of new drug molecules entering human clinical trials globally [4] - The Hong Kong Stock Connect Medical ETF focuses on capturing investment opportunities in the pharmaceutical sector, including medical devices, drugs, biotechnology, and medical services [4]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug 50 ETF (513780) leading the market with a year-to-date increase of over 112% [2] Group 1: Market Performance - The Hong Kong Innovative Drug 50 ETF (513780) has seen a net inflow of 800 million yuan in the last 20 days, with a total net inflow exceeding 2 billion yuan this year, bringing its latest scale to 2.712 billion yuan [2] - The ETF is noted for having the largest scale and best liquidity among its peers, allowing for T+0 trading [2] Group 2: Composition and Holdings - The index tracked by the Hong Kong Innovative Drug 50 ETF consists solely of innovative drug companies, with major holdings including industry leaders such as CanSino Biologics, Innovent Biologics, WuXi Biologics, BeiGene, China National Pharmaceutical Group, CSPC Pharmaceutical Group, Hansoh Pharmaceutical, WuXi AppTec, and 3SBio [2] Group 3: Future Outlook - CITIC Securities anticipates an increase in innovative drug catalyst events in September, suggesting that the recent technology switch has cleared out short-term speculative money from the sector, which may allow innovative drugs to continue their upward trend after recent adjustments [2]

Group 1 - The Hong Kong stock market for innovative drug concept stocks is showing strength, with companies like BeiGene rising over 6%, 3SBio increasing over 3%, and WuXi Biologics up over 2% [1] - Several Hong Kong innovative drug-related ETFs have also increased by over 2% due to market influences [2] - Specific ETFs such as the Hong Kong Innovative Drug ETF T+0 and the Hong Kong Innovative Drug Selected ETF have reported gains of 3.24% and 2.47% respectively [3] Group 2 - Upcoming global conferences, including the World Conference on Lung Cancer (WCLC) in September and the European Society for Medical Oncology (ESMO) in October, will showcase research results from domestic innovative drugs [3] - Notable products to be presented include AK112 from CanSino Biologics and DB-1311 from InnoCare Pharma, highlighting the increasing competitiveness of domestic innovative drugs in clinical data and progress [3] - The trend of innovative drugs going global is strengthening as domestic companies enhance their clinical capabilities [3]

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-09-02 宏观策略 [Table_MacroStrategy] 宏观深度报告 20250901：补贴与竞争：哪些地区和行业内卷更严重？— —统一大市场系列研究之一 土地补贴和财税补贴是地方政府间横向竞争的工具。我们尝试量化产业 政策中土地和财税补贴的规模，并识别哪些地区和行业的税负率更低。土 地补贴方面，按照价差计算，2017-2024 年 70 城工业部门获得的土地补 贴年均 1.45 万亿，占全国 GDP 的 1.3%左右；财税补贴方面，按照与法 定税率的差距来算，2023 年制造业的企业所得税税收优惠约 7300 亿，占 GDP 的 0.56%。结合地区和行业来看，可以识别内卷程度，汽车制造业、 电气机械、电子设备等行业大多是中西部省份内卷更严重，存在利润率和 税负率双低的情况，具体见 2.2.4。近年来，面临房地产市场下行、"反内 卷"规范地方政府补贴、消费税改革等三大变革，传统的横向竞争模式正 在迎来转变，地方政府将从"逐底竞争"转向"逐顶竞争"。 风险提示： （1）房地产和土地市场变化，对地方政府行为影响较大，如果未来房地 产市场出现趋 ...

Key Points - The top three companies with net inflow of southbound funds are SMIC (8.86 billion), Kangfang Biotech (6.32 billion), and Huahong Semiconductor (4.63 billion) [1] - The top three companies with net outflow of southbound funds are the Tracker Fund of Hong Kong (-11.887 billion), Hang Seng China Enterprises (-5.878 billion), and Southern Hang Seng Technology (-1.359 billion) [1] - In terms of net inflow ratio, China Overseas Macro Group (61.54%), Hopson Development Holdings (54.61%), and Hong Kong and China Gas (53.29%) lead the market [1] - The companies with the highest net outflow ratio are Jinke Services (-85.01%), BOC Aviation (-63.04%), and Ansteel (-57.57%) [1] Net Inflow Rankings - SMIC (00981) had a net inflow of 8.86 billion with a 4.46% increase in closing price to 62.300 [2] - Kangfang Biotech (09926) saw a net inflow of 6.32 billion but a decrease of 3.06% in closing price to 152.200 [2] - Huahong Semiconductor (01347) recorded a net inflow of 4.63 billion with an 8.44% increase in closing price to 57.200 [2] Net Outflow Rankings - The Tracker Fund of Hong Kong (02800) experienced the largest net outflow of -11.887 billion with a closing price of 25.500, down 0.78% [2] - Hang Seng China Enterprises (02828) had a net outflow of -5.878 billion and closed at 91.240, down 1.15% [2] - Southern Hang Seng Technology (03033) saw a net outflow of -1.359 billion with a closing price of 5.545, down 0.89% [2] Net Inflow Ratio Rankings - China Overseas Macro Group had a net inflow ratio of 61.54% with a net inflow of 13.6562 million and a closing price of 2.210, up 0.45% [3] - Hopson Development Holdings achieved a net inflow ratio of 54.61% with a net inflow of 6.3567 million and a closing price of 3.710, down 1.07% [3] - Hong Kong and China Gas recorded a net inflow ratio of 53.29% with a net inflow of 19.6320 million and a closing price of 4.040, down 0.49% [3] Net Outflow Ratio Rankings - Jinke Services had the highest net outflow ratio of -85.01% with a net outflow of -12.5979 million and a closing price of 6.450, up 1.10% [3] - BOC Aviation recorded a net outflow ratio of -63.04% with a net outflow of -82.3925 million and a closing price of 68.750, down 2.27% [3] - Ansteel had a net outflow ratio of -57.57% with a net outflow of -25.7369 million and a closing price of 2.110, down 1.86% [3]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.67% on September 1, with a trading volume of 1.985 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of August 29, 2024, the fund's latest share count was 6.686 billion, with a total size of 6.403 billion yuan, reflecting a year-to-date increase of 1591.03% in shares and 1594.74% in size compared to the end of 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 91.54% during the tenure [2] - The top holdings of the fund include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings in the portfolio [2] - The fund's liquidity is strong, with a cumulative trading amount of 34.181 billion yuan over the last 20 trading days, averaging 1.709 billion yuan per day [1]

Core Viewpoint - The report from Credit Lyonnais raises the target price for Kangfang Biotech (09926) from HKD 112.6 to HKD 177, maintaining an outperform rating, indicating strong confidence in the company's future performance [1] Sales and Profit Forecast - The company is expected to achieve a year-on-year sales growth of 33.7% in the first half of 2025, which aligns with market expectations [1] - Sales forecasts for Kangfang Biotech for 2025 to 2027 have been adjusted upwards by 1.2%, 5.1%, and 18.9% respectively [1] - Net profit forecasts for the fiscal years 2026 and 2027 have been increased by 10.9% and 35% respectively [1] Clinical Trial Results - The analysis results for AK112's overall survival (OS) are statistically significant and clinically meaningful, providing positive insights for the overseas HARMONi trial [1]

Core Viewpoint - The report from Credit Lyonnais indicates a target price increase for Kangfang Biotech (09926) from HKD 112.6 to HKD 177, maintaining an outperform rating [1] Sales Forecast - The company is expected to achieve a year-on-year sales growth of 33.7% in the first half of 2025, which aligns with market expectations [1] - Sales forecasts for Kangfang Biotech for 2025 to 2027 have been revised upward by 1.2%, 5.1%, and 18.9% respectively [1] Profit Forecast - Net profit estimates for the fiscal years 2026 and 2027 have been increased by 10.9% and 35% respectively [1] Clinical Results - The overall survival (OS) analysis results for AK112 are statistically significant and clinically meaningful, providing positive reference for the overseas HARMONi trial [1]

Group 1 - The Hong Kong pharmaceutical sector experienced a significant rise, with the Hang Seng Biotechnology Index closing up over 5%, driven by favorable policies and strong performance in earnings [1] - The National Healthcare Security Administration announced the adjustment list for the 2025 medical insurance and commercial insurance innovative drug directory, which includes several heavyweight innovative drugs, enhancing market access expectations [1] - Several pharmaceutical companies reported robust performance in the first half of the year, such as BeiGene with a 46% year-on-year revenue growth and achieving half-year profitability for the first time, and Heng Rui Medicine reaching record highs in revenue and profit, improving the sector's attractiveness [1] Group 2 - The international collaboration and overseas expansion of innovative drugs have become significant catalysts, with Chinese pharmaceutical companies completing 83 license-out transactions totaling over $84.5 billion, setting a historical record [1] - The partnership between 3SBio and Pfizer, valued at $6.05 billion for dual antibody licensing, highlights global market recognition of domestic innovative drugs [1] - Hong Kong has recently introduced simplified registration policies that recognize mainland review data, facilitating internationalization for innovative drug companies and further expanding industry growth potential [3] Group 3 - The upcoming global academic conferences, such as the World Lung Cancer Conference in September and the European Society for Medical Oncology Annual Meeting in October, will see multiple companies showcasing core clinical data, which may serve as short-term stock price catalysts [3] - Institutions believe that the long-term logic of the innovative drug sector remains unchanged, and the expectation of interest rate cuts by the Federal Reserve is strengthening liquidity, leading to continued capital allocation towards leading Hong Kong pharmaceutical stocks [4]